

REFERENCES

- Nicolai L, Leunig A, Pekayvaz K, et al. Thrombocytopenia and splenic platelet directed immune responses after IV ChAdOx1 nCov-19 administration. *Blood*. 2022;140(5):478-490.
- Zandvoort A, Timens W. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. *Clin Exp Immunol*. 2002;130(1):4-11.
- Rinaldi M, Perricone C, Ortega-Hernandez OD, Perricone R, Shoenfeld Y. Immune thrombocytopenic purpura: an autoimmune cross-link between infections and vaccines. *Lupus*. 2014;23(6):554-567.
- Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of *Helicobacter pylori*. *Lancet*. 1998;352(9131):878.
- Nardi M, Karparkin S. Antidiotype antibody against platelet anti-GPIIb contributes to the regulation of thrombocytopenia in HIV-1-ITP patients. *J Exp Med*. 2000;191(12):2093-2100.
- Craven B, Lester W, Boyce S, et al. Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis. *Blood*. 2022;139(16):2553-2560.
- Michalik S, Siegerist F, Palankar R, et al. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines. *Haematologica*. 2022;107(4):947-957.
- Khandelwal S, Barnes A, Rauova L, et al. Complement mediates binding and procoagulant effects of ultra-large HIT immune complexes. *Blood*. 2021;138(21):2106-2116.
- Zheng Y, Wang AW, Yu M, et al. B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. *Blood*. 2014;123(6):931-934.

DOI 10.1182/blood.2022016773

© 2022 by The American Society of Hematology

LYMPHOID NEOPLASIA

Comment on Jain et al, page 491, and Cherng et al, page 504

Tumor-intrinsic causes of CAR-T failure


Helen E. Heslop | Baylor College of Medicine

In this issue of *Blood*, two reports delineate tumor-specific factors associated with clinical responses to infusion of approved T-cell products genetically modified with a chimeric antigen receptor (CAR) targeting CD19 in patients with diffuse large B-cell lymphoma (DLBCL)^{1,2} (see figure). Jain et al comprehensively characterized the genomes of lymphoma tissue from patients who received CD19 CAR-T cells and report that genome-wide mutational signatures and patterns of structural alterations are associated with CAR-T cell response. Cherng et al evaluated circulating tumor DNA and show that a high focal copy number alterations (CNAs) score, denoting genomic instability, was the most significant pretreatment variable associated with poor response to CAR-T therapy or subsequent relapse.

Autologous CD19 CAR-T cells have significant therapeutic benefit for patients with relapsed/refractory DLBCL, and 3 products have obtained Food and Drug Administration approval. Since the first approvals in 2017, the therapy has been used in several thousand patients, and “real-world” analyses confirmed the initial response rates of 50% to 80% reported in the studies that led to licensure.³⁻⁷ However, more than half of recipients experience relapse and disease progression, with prolonged

disease responses in only ~40%.^{3,7} Therefore, predictive factors for subsequent progression or relapse would be useful to identify patients who may benefit from combination therapies or additional consolidation strategies.

A number of studies have investigated the infused cell product or host immune system to identify factors associated with poor outcomes. These reports correlated serum inflammatory markers and T-cell



Blood draw and low-pass whole-genome sequencing of cell free DNA (Cherng et al)

Tumor biopsy followed by whole-genome sequencing (Jain et al)

Two papers interrogate the lymphoma genome to learn causes of CAR-T failure in patients with diffuse B-cell lymphoma. Jain et al evaluate tumor biopsies with WGS, whereas Cherng et al perform low-pass WGS on circulating tumor DNA derived from peripheral blood. Professional illustration by Somersault18:24.

exhaustion in either the CAR-19 products or the recipient with poor outcomes.^{8,9} The studies in this issue of *Blood* instead examined tumor-intrinsic factors that may lead to clinical CD19 CAR-T cell failures through whole-genome sequencing (WGS) of the tumor or low-pass WGS of cell-free DNA from plasma.

The first study from Jain et al at Moffitt Cancer Center and the University of Miami used WGS to assess tumor samples from 49 patients with DLBCL treated with axicabtagene ciloleucel and found that pretreatment presence of complex structural variants, APOBEC mutational signatures, and genomic damage from reactive oxygen species predicted CAR-19 resistance. In addition, the recurrent 3p21.31 chromosomal deletion containing the *RHOA* tumor suppressor was strongly enriched in patients who failed CAR-T therapy. Of note, reduced CD19 expression, which has been identified as a mechanism of failure in CD19 CAR-T cell therapy for acute lymphoblastic leukemia with tisagenlecleucel, did not affect responses in this study. One limitation of the WGS strategy used in this study is that it requires viable lymphoma tumor tissue and matched germline DNA.

Cell-free DNA provides an alternative strategy for evaluating tumor genetic changes¹⁰ and, in the second report, Cherng and colleagues at MD Anderson Cancer Center used a less-intensive assay requiring only a peripheral blood sample to evaluate CNAs. The authors undertook low-pass WGS of cell-free DNA from blood samples collected at the time of leukapheresis for product manufacture and analyzed samples from 122 patients (92% of whom received axicabtagene ciloleucel and 8% of whom received tisagenlecleucel). In multivariable analysis, Cherng et al found that a high focal CNAs score was the most significant pretreatment variable associated with inferior 3-month complete response rates and overall and progression-free survival. The study identified 34 unique focal CNAs, with deletion 10q23.3 leading to loss of *FAS* death receptor being the most prognostic for poor outcomes. By combining focal CNAs score with standard markers of increased tumor bulk (elevated lactate dehydrogenase and disease at >1 extranodal site), this study builds a risk model that may reliably stratify patients.

Both studies were retrospective and conducted at a single institution in 1 case and 2 institutions in the other, so require validation in other cohorts. In addition, both studies predominantly included patients who received axicabtagene ciloleucel. Whether these observations also apply to the other 2 commercial products thus remains to be seen. Nevertheless, these studies provide tumor-specific predictive factors that could be used to identify patients at high risk of relapse following CD19 CAR-T cells who may need additional therapies. Integrating these tumor-specific risk factors with other host and product factors that influence outcome may produce even stronger algorithms to predict success or failure.

Conflict-of-interest disclosure: The author has equity in Allovir and Marker Therapeutics, has served on advisory boards for Tessa Therapeutics, Novartis, Gilead, GSK, Kiadis, and Fresh Wind Biotechnologies, and received research support from Tessa Therapeutics and Kur Therapeutics. ■

REFERENCES

1. Jain MD, Ziccheddu B, Coughlin CA, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. *Blood*. 2022;140(5):491-503.
2. Cherng H-JJ, Sun R, Sugg B, et al. Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma. *Blood*. 2022;140(5):504-515.
3. Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. *J Clin Oncol*. 2020;38(27):3095-3106.
4. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med*. 2017;377(26):2531-2544.
5. Schuster SJ, Bishop MR, Tam CS, et al; JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med*. 2019;380(1):45-56.
6. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. *Lancet*. 2020;396(10254):839-852.
7. Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. *J Clin Oncol*. 2020;38(27):3119-3128.
8. Deng Q, Han G, Puebla-Osorio N, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. *Nat Med*. 2020;26(12):1878-1887.
9. Jain MD, Zhao H, Wang X, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. *Blood*. 2021;137(19):2621-2633.
10. Roschewski M, Rossi D, Kurtz DM, Alizadeh AA, Wilson WH. Circulating tumor DNA in lymphoma: principles and future directions. *Blood Cancer Discov*. 2022;3(1):5-15.

DOI 10.1182/blood.2022016851

© 2022 by The American Society of Hematology

MYELOID NEOPLASIA

Comment on Li et al, page 516

AML: making residual disease more measurable

Maria Teresa Voso¹ and Francesco Buccisano¹ | University of Rome Tor Vergata

In this issue of *Blood*, Li et al¹ show that detection of leukemic stem cells (LSCs) may predict relapse and overall survival (OS) after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML) better than classical measurable residual disease (MRD) by multiparameter flow cytometry (MFC).

The power of MRD to predict outcome in AML has long been established and led to the inclusion of MRD positivity after induction or consolidation chemotherapy as one of the factors that define high-risk AML (see

Figure). The importance of MRD is emphasized by the inclusion of MRD-negative complete remission (CR) as a treatment goal in AML in the 2017 and 2021 European LeukemiaNet (ELN) MRD guidelines.²